{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:16:16Z","timestamp":1773875776129,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Incidence and risk factors for seizures among women with advanced breast cancer (BC) and brain metastases are not well characterized across treatment-related or clinical subtypes. This study leveraged a large real-world dataset to describe incidence and risk factors for seizures in <jats:italic>BRCA<\/jats:italic>-associated metastatic breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Optum\u00ae de-identified electronic health records database was used. Females with a BC diagnoses between 2008 and 2018, with clinic visits 12\u2009months before BC index date, evidence of <jats:italic>BRCA<\/jats:italic> mutation (<jats:italic>BRCA<\/jats:italic>+), evidence of metastasis, and no previous cancers were included. Analyses were stratified by the overall <jats:italic>BRCA+<\/jats:italic> cohort and 4 molecular phenotypes: HER2+\/HR- (human epidermal growth factor 2\/hormone receptor), HER2\u2212\/HR+, HER2+\/HR+, and triple negative BC (TNBC; HER2\u2212\/HR-). Seizures were identified using diagnosis codes and natural language processing. Incidence, occurrence rates, and cumulative incidence of seizures from the diagnosis of metastasis to the end of follow up were calculated. Comparisons were made between phenotypes and stratified on PARP inhibitor use, diagnosed brain metastases, history of seizures, and anticonvulsants use before BC. All comparisons included age at metastasis, number of prior lines of treatment, and metastasis location as covariates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>27.8% of 7941 <jats:italic>BRCA+<\/jats:italic> patients had \u22651 seizure over a mean follow-up time of 2.35\u2009years. Incidence and occurrence rates were 11.83 (95% CI: 11.35\u201312.33) and 201.3 (95% CI: 198.05\u2013204.50), respectively, per 100 person-years. HER2\u2212\/HR+ and TNBC patients had the lowest and highest seizure incidence rates, respectively (10.94 [95% CI: 10.23\u201311.71] and 16.83 [95% CI: 15.34\u201318.46]). With HER2\u2212\/HR+ as the reference group in a competing risk analysis, TNBC (hazard ratio, HR\u2009=\u20091.35; 95%CI: 1.21, 1.52; <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001) and HER2+\/HR- (HR\u2009=\u20091.29; 95%CI: 1.07, 1.56; <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01) patients had a greater risk of seizures. Patients with diagnosed brain metastases or a history of seizures had higher seizure rates. Incidence trended higher with PARP inhibitor use, but patient numbers were low.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study provides novel real-world evidence on seizure incidence rates in <jats:italic>BRCA<\/jats:italic>+ BC patients, even those without diagnosed brain metastases, and underscores the need to understand patients\u2019 tumor phenotypes when assessing seizure risk. These findings may have implications for clinical practice and assessment of benefit-risk ratios of new therapeutic agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-10554-6","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:03:51Z","timestamp":1674518631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States"],"prefix":"10.1186","volume":"23","author":[{"given":"Alexander","family":"Liede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Sebby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok Kumar Reddy","family":"Miriyala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eros","family":"Papademetriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy E.","family":"Tyczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"issue":"1","key":"10554_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10554_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721\u201330.","journal-title":"Cancer"},{"issue":"23","key":"10554_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"key":"10554_CR4","first-page":"227","volume":"13","author":"S Peleg Hasson","year":"2020","unstructured":"Peleg Hasson S, Menes T, Sonnenblick A. Comparison of patient susceptibility genes across breast Cancer: implications for prognosis and therapeutic outcomes. Pharmgenomics Pers Med. 2020;13:227\u201338.","journal-title":"Pharmgenomics Pers Med"},{"key":"10554_CR5","unstructured":"Cancer stat facts: female breast cancer [https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html]."},{"issue":"7418","key":"10554_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"8","key":"10554_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","volume":"27","author":"C Winter","year":"2016","unstructured":"Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27(8):1532\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"10554_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer treatment: a review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"19","key":"10554_CR9","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast Cancer. J Clin Oncol. 2017;35(19):2141\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"10554_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"issue":"32","key":"10554_CR11","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1200\/JCO.2015.61.5831","volume":"33","author":"MJ Ellis","year":"2015","unstructured":"Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasi\u00f3wka M, Hewson N, et al. Fulvestrant 500 mg versus Anastrozole 1 mg for the FIRST-line treatment of advanced breast Cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33(32):3781\u20137.","journal-title":"J Clin Oncol"},{"key":"10554_CR12","volume-title":"NCCN Guidelines Version 6.2020 Breast Cancer","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Guidelines Version 6.2020 Breast Cancer. PA, USA: National Comprehensive Cancer Network: Plymouth Meeting; 2020."},{"issue":"6","key":"10554_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"10554_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast Cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"3","key":"10554_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11060-016-2075-3","volume":"127","author":"R Rostami","year":"2016","unstructured":"Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neuro-Oncol. 2016;127(3):407\u201314.","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"10554_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/jon.12149","volume":"25","author":"RH Yeh","year":"2015","unstructured":"Yeh RH, Yu JC, Chu CH, Ho CL, Kao HW, Liao GS, et al. Distinct MR imaging features of triple-negative breast Cancer with brain metastasis. J Neuroimaging. 2015;25(3):474\u201381.","journal-title":"J Neuroimaging"},{"issue":"12","key":"10554_CR17","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1002\/cncr.23088","volume":"110","author":"K Altundag","year":"2007","unstructured":"Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110(12):2640\u20137.","journal-title":"Cancer"},{"issue":"6","key":"10554_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/00019052-199612000-00005","volume":"9","author":"JG Villemure","year":"1996","unstructured":"Villemure JG, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol. 1996;9(6):424\u20138.","journal-title":"Curr Opin Neurol"},{"issue":"9 Suppl 5","key":"10554_CR19","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1212\/WNL.59.9_suppl_5.S21","volume":"59","author":"ST Herman","year":"2002","unstructured":"Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology. 2002;59(9 Suppl 5):S21\u20136.","journal-title":"Neurology"},{"issue":"5","key":"10554_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","volume":"6","author":"MS van Breemen","year":"2007","unstructured":"van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421\u201330.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"10554_CR21","first-page":"S27","volume":"1","author":"EB Bromfield","year":"2004","unstructured":"Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis. 2004;1(Suppl 1):S27\u201333.","journal-title":"Rev Neurol Dis"},{"issue":"5","key":"10554_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00280-008-0876-6","volume":"63","author":"C Sioka","year":"2009","unstructured":"Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63(5):761\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10554_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00280-011-1569-0","volume":"67","author":"O Kargiotis","year":"2011","unstructured":"Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer Chemother Pharmacol. 2011;67(3):489\u2013501.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10554_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","volume":"33","author":"PJ Wallace","year":"2014","unstructured":"Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33(7):1187\u201394.","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10554_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/dom.13937","volume":"22","author":"JH Pettus","year":"2020","unstructured":"Pettus JH, Zhou FL, Shepherd L, Mercaldi K, Preblick R, Hunt PR, et al. Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: a real-world study of more than 30\u2009000 patients in a US electronic health record database. Diabetes Obes Metab. 2020;22(4):622\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"10554_CR26","volume-title":"Health insurance portability and accountability act (HIPAA)","author":"PF Edemekong","year":"2020","unstructured":"Edemekong PF, Annamaraju P, Haydel MJ. Health insurance portability and accountability act (HIPAA). Treasure Island (FL): StatPearls Publishing LLC; 2020."},{"issue":"4","key":"10554_CR27","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/rth2.12333","volume":"4","author":"CM Broome","year":"2020","unstructured":"Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;4(4):628\u201335.","journal-title":"Res Pract Thromb Haemost"},{"key":"10554_CR28","first-page":"58","volume-title":"35th international conference on Pharmacoepidemiology and risk management (ICPE): august 28, 2019","author":"R Jiang","year":"2019","unstructured":"Jiang R, Potluri R. Contribution of natural language processing in predicting risk of pleural and pericardial effusions in small cell lung Cancer by line of therapy. In: 35th international conference on Pharmacoepidemiology and risk management (ICPE): august 28, 2019. Philadelphia, Pennsylvania: International Society for Pharmacoepidemiology; 2019. p. 58."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-10554-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:04:08Z","timestamp":1674518648000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10554"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-10554-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a retrospective analysis of deidentified data from a US based proprietary database. The data is a limited data set with data use agreements in place for use. It only contains de-identified health information that, as described by the HIPPA Privacy Rule, is not PHI. A limited dataset excludes specified direct identifiers of the individual or of relatives, employers, or household members of the individual. The Optum EHR database meets these criteria. Access to and use of the data available only through a license agreement. The license (obtained by AbbVie) describes the data, limitations on use, limitations on users and specifically prohibits re-identification. It also includes reference to the HIPPA Privacy Rule: 45 CFR 164.501, 164.508, 164.512(i). For these reasons, our data is not covered by the Privacy Rule and IRB approval was\u2019t required. As this was an observational retrospective study, there was no experimental protocol, however, all analyses were approved by the sponsor (AbbVie). All procedures were performed in accordance with relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Individual patient data in the database from which this dataset was derived are deidentified and consent for publication is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WS, AKRM, RK, & AL are all employees of AbbVie and own stock. At the time the study was conducted, JET was an employee of AbbVie. RP, DM, AG, EP are employed by SmartAnalyst and received funding from AbbVie to conduct the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}